Trade Bolt Biotherapeutics, Inc. - BOLT CFD
Add to favourite- Summary
- Historical Data
Spread | 0.0262 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 1.1069 |
Open | 1.0869 |
1-Year Change | -28.37% |
Day's Range | 1.0869 - 1.1869 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 24, 2024 | 1.1869 | 0.1000 | 9.20% | 1.0869 | 1.1969 | 1.0869 |
Apr 23, 2024 | 1.1069 | 0.0200 | 1.84% | 1.0869 | 1.1069 | 1.0869 |
Apr 22, 2024 | 1.0869 | -0.0100 | -0.91% | 1.0969 | 1.1069 | 1.0869 |
Apr 19, 2024 | 1.1069 | -0.0300 | -2.64% | 1.1369 | 1.1469 | 1.1069 |
Apr 18, 2024 | 1.1369 | 0.0300 | 2.71% | 1.1069 | 1.1469 | 1.0969 |
Apr 17, 2024 | 1.1069 | -0.0100 | -0.90% | 1.1169 | 1.1269 | 1.0969 |
Apr 16, 2024 | 1.1169 | 0.0000 | 0.00% | 1.1169 | 1.1369 | 1.0769 |
Apr 15, 2024 | 1.1269 | -0.0400 | -3.43% | 1.1669 | 1.1669 | 1.0969 |
Apr 12, 2024 | 1.1769 | -0.0700 | -5.61% | 1.2469 | 1.2669 | 1.1569 |
Apr 11, 2024 | 1.2469 | 0.0100 | 0.81% | 1.2369 | 1.2569 | 1.2369 |
Apr 10, 2024 | 1.2469 | -0.0100 | -0.80% | 1.2569 | 1.2669 | 1.2169 |
Apr 9, 2024 | 1.2669 | -0.0500 | -3.80% | 1.3169 | 1.3169 | 1.2369 |
Apr 8, 2024 | 1.3669 | 0.0000 | 0.00% | 1.3669 | 1.3669 | 1.2969 |
Apr 5, 2024 | 1.3269 | -0.0400 | -2.93% | 1.3669 | 1.3669 | 1.3069 |
Apr 4, 2024 | 1.3169 | -0.0100 | -0.75% | 1.3269 | 1.3469 | 1.3069 |
Apr 3, 2024 | 1.3269 | -0.0300 | -2.21% | 1.3569 | 1.4569 | 1.2869 |
Apr 2, 2024 | 1.3769 | -0.0300 | -2.13% | 1.4069 | 1.4569 | 1.3269 |
Apr 1, 2024 | 1.4869 | 0.0900 | 6.44% | 1.3969 | 1.5469 | 1.3369 |
Mar 28, 2024 | 1.3769 | 0.1700 | 14.09% | 1.2069 | 1.4569 | 1.2069 |
Mar 27, 2024 | 1.1969 | 0.0300 | 2.57% | 1.1669 | 1.2069 | 1.1669 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Bolt Biotherapeutics, Inc. Company profile
About Bolt Biotherapeutics Inc
Bolt Biotherapeutics, Inc is a clinical-stage immuno-oncology company. The Company is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Its Immune-Stimulating Antibody Conjugate (ISAC) approach uses immunostimulants to engage and activate myeloid cells, including macrophages and dendritic cells, that kill tumor cells via phagocytosis and expose tumor neoantigens to the adaptive immune system. The Company’s product candidate BDC-1001 is a human epidermal growth factor receptor 2 (HER2) Boltbody ISAC comprised of a HER2-targeting biosimilar, of trastuzumab conjugated to one of its TLR7/8 agonists, for the treatment of patients with HER2-expressing solid tumors, including those with HER2-low tumors. Its Toll-like receptors (TLRs) activate myeloid cells and enable the presentation of tumor-associated neoantigens to cytotoxic T cells.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Bolt Biotherapeutics Inc revenues increased from $231K to $752K. Net loss increased from $29.7M to $71.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and d increase of 99% to $49.8M (expense), Fair Value Adjustments on Other Assets decrease from $2.4M (income) to $6.1M (expense).
Industry: | Bio Therapeutic Drugs |
900 Chesapeake Drive
REDWOOD CITY
CALIFORNIA 94063
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com